GigaGen Doses 1st Patient in Phase 1 Trial of GIGA-2339, Potential Functional Cure for Chronic HBV

Описание к видео GigaGen Doses 1st Patient in Phase 1 Trial of GIGA-2339, Potential Functional Cure for Chronic HBV

Carter Keller discussed GIGA-2339, a recombinant polyclonal antibody developed by GigaGen Inc, which combines over 1,000 human antibodies to target the Hepatitis B surface antigen (HBsAg), aiming to clear the virus and activate the immune system. This approach offers a potential solution where current HBV therapies fall short, as existing treatments can suppress the virus but do not provide a cure. GIGA-2339 is designed to target a broad range of HBV variants, including escape mutations, and may lead to a functional cure for chronic HBV.

Комментарии

Информация по комментариям в разработке

Похожие видео